98 results on '"Steelant B"'
Search Results
2. Nasal hyperreactivity in allergic rhinitis and chronic rhinosinusitis with polyps: a role for neuronal pathways
- Author
-
Backaert, W, primary, Steelant, B, additional, Wils, T, additional, Qian, Z, additional, Dilissen, E, additional, Jonckheere, A-C, additional, Boonen, B, additional, Jorissen, M, additional, Schrijvers, R, additional, Bullens, D M A, additional, Talavera, K, additional, Hellings, P W, additional, and Van Gerven, L, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Histamine and IL-4 alter airway basal cell differentiation and mobility after injury
- Author
-
Ruysseveldt, E, primary, Wils, T, additional, Cremer, J, additional, Martens, K, additional, Hellings, P, additional, and Steelant, B, additional
- Published
- 2023
- Full Text
- View/download PDF
4. The potential role of innate lymphoid cells in non-allergic neutrophilic asthma model
- Author
-
Jonckheere, A, primary, Steelant, B, additional, Seys, S, additional, Decaesteker, T, additional, Cremer, J, additional, Dilissen, E, additional, Schols, D, additional, Iwakura, Y, additional, Vanoirbeek, J, additional, Dupont, L, additional, and Bullens, D, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Therapeutic effect of capsaicin nasal treatment in patients with mixed rhinitis unresponsive to intranasal steroids
- Author
-
Van Gerven, L., Steelant, B., Alpizar, Y. A., Talavera, K., and Hellings, P. W.
- Published
- 2018
- Full Text
- View/download PDF
6. Determination of the chronic upper airway inflammatory phenotype using a symptom-score-based algorithm
- Author
-
Backaert, W., primary, Steelant, B., additional, Guler, I., additional, Talavera, K., additional, Jorissen, M., additional, Schrijvers, R., additional, Hellings, P.W., additional, and Van Gerven, L., additional
- Published
- 2022
- Full Text
- View/download PDF
7. European symposium on the awareness of allergy: report of the promotional campaign in the European Parliament (26–28 April 2016)
- Author
-
Muraro, A., Steelant, B., Pietikainen, S., Borrelli, D., Childers, N., Callebaut, I., Kortekaas Krohn, I., Martens, K., Pugin, B., Popescu, F.‐D., Vieru, M., Jutel, M., Agache, I., and Hellings, P. W.
- Published
- 2017
- Full Text
- View/download PDF
8. Occupational upper airway disease: how work affects the nose
- Author
-
Hox, V., Steelant, B., Fokkens, W., Nemery, B., and Hellings, P. W.
- Published
- 2014
- Full Text
- View/download PDF
9. Probiotics for the airways: Potential to improve epithelial and immune homeostasis
- Author
-
Martens, K., primary, Pugin, B., additional, De Boeck, I., additional, Spacova, I., additional, Steelant, B., additional, Seys, S. F., additional, Lebeer, S., additional, and Hellings, P. W., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge
- Author
-
Van Gerven, L., primary, Steelant, B., additional, and Hellings, P. W., additional
- Published
- 2018
- Full Text
- View/download PDF
11. EUFOREA Rhinology Research Forum 2017: report of the brainstorming sessions on endotype-driven treatment, patient empowerment and digital future in airways care
- Author
-
Lund, V.J., primary, Hopkins, C., additional, Akdis, C., additional, Bachert, C., additional, Bousquet, J., additional, Fokkens, W.J., additional, Seys, S., additional, Van Gerven, L., additional, Akdis, M., additional, Ban, G.Y., additional, Biswas, K., additional, Boscke, R., additional, Boeva, V., additional, Canonica, G.W., additional, Castillo, J.A., additional, Chung, S.K., additional, Claes, J.A.M., additional, Cools, L., additional, De Carlo, G., additional, De Corso, E., additional, Djandji, M., additional, Doulaptsi, M., additional, Feijen, J., additional, Gallo, S., additional, Gane, S., additional, Gevaert, P., additional, Golebski, K., additional, Halewyck, S., additional, Hummel, T., additional, Izquierdo, I., additional, Jagerschmidt, A., additional, Joos, G.F., additional, Kjeldsen, A.D., additional, Kloeck, I., additional, Koennecke, M., additional, Kokorina, O., additional, Koren, I., additional, Kortekaas-Krohn, I., additional, Krysko, O., additional, Landis, B.N., additional, Lange, B., additional, Launders, N., additional, Lee, J., additional, Lekakis, G., additional, Mannent, L., additional, Martens, K., additional, Morghenti, D., additional, Mullol, J., additional, Murray, R., additional, O'Sullivan, D., additional, Philpott, C., additional, Popov, T.A., additional, Prokopakis, E., additional, Rombaux, P., additional, Rondon, C., additional, Rowe, P.J., additional, Seyed-Tabib, N.S., additional, Sleurs, K., additional, Speleman, K.J.S., additional, Staikuniene, J., additional, Steelant, B., additional, Talavera-Perez, K., additional, Taube, C., additional, Toppila-Salmi, S., additional, Tran-Le, T., additional, Vaitkus, J., additional, Vaitkus, S., additional, Van Gool, K., additional, Van Hoolst, A., additional, Verbrugge, R., additional, Verhaeghe, B., additional, Vlaminck, S., additional, Wagenmann, M., additional, Zuberbier, T., additional, Tasman, A.-J., additional, Pugin, B., additional, and Hellings, P.W., additional
- Published
- 2018
- Full Text
- View/download PDF
12. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis
- Author
-
Hellings, PW, Akdis, CA, Bachert, C, Bousquet, J, Pugin, B, Adriaensen, G, Advani, R, Agache, I, Anjo, C, Anmolsingh, R, Annoni, E, Bieber, T, Bizaki, A, Braverman, I, Callebaut, I, Castillo Vizuete, JA, Chalermwatanachai, T, Chmielewski, R, Cingi, C, Cools, L, Coppije, C, Cornet, M, De Boeck, I, De Corso, E, De Greve, G, Doulaptsi, M, Erskine, S, Gevaert, E, Gevaert, P, Golebski, K, Hopkins, C, Hox, V, Jaeggi, C, Joos, G, Khwaja, S, Kjeldsen, A, Klimek, L, Koennecke, M, Kortekaas Krohn, I, Krysko, O, Kumar, BN, Langdon, C, Lange, B, Lekakis, G, Levie, P, Lourijsen, E, Lund, V, Martens, K, Mösges, R, Mullol, J, Nyembue, TD, Palkonen, S, Philpott, C, Pimentel, J, Poirrier, A, Pratas, AC, Prokopakis, E, Pujols, L, Rombaux, P, Schmidt-Weber, C, Segboer, C, Spacova, I, Staikuniene, J, Steelant, B, Steinsvik, EA, Teufelberger, A, Van Gerven, L, Van Gool, K, Verbrugge, R, Verhaeghe, B, Virkkula, P, Vlaminck, S, Vries-Uss, E, Wagenmann, M, Zuberbier, T, Seys, SF, and Fokkens, WJ
- Abstract
The first European Rhinology Research Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held in the Royal Academy of Medicine in Brussels on 17th and 18th November 2016, in collaboration with the European Rhinologic Society (ERS) and the Global Allergy and Asthma European Network (GA2LEN). One hundred and thirty participants (medical doctors from different specialties, researchers, as well as patients and industry representatives) from 27 countries took part in the multiple perspective discussions including brainstorming sessions on care pathways and research needs in rhinitis and rhinosinusitis. The debates started with an overview of the current state of the art, including weaknesses and strengths of the current practices, followed by the identification of essential research needs, thoroughly integrated in the context of Precision Medicine (PM), with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key principles for improving current clinical practices. This report provides a concise summary of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2016.
- Published
- 2017
13. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis
- Author
-
Kortekaas Krohn, I., primary, Callebaut, I., additional, Alpizar, Y. A., additional, Steelant, B., additional, Van Gerven, L., additional, Skov, P. S., additional, Kasran, A., additional, Talavera, K., additional, Wouters, M. M., additional, Ceuppens, J. L., additional, Seys, S. F., additional, and Hellings, P. W., additional
- Published
- 2018
- Full Text
- View/download PDF
14. Therapeutic effect of capsaicin nasal treatment in patients with mixed rhinitis unresponsive to intranasal steroids
- Author
-
Van Gerven, L., primary, Steelant, B., additional, Alpizar, Y. A., additional, Talavera, K., additional, and Hellings, P. W., additional
- Published
- 2017
- Full Text
- View/download PDF
15. Programmed cell death‐1 expression correlates with disease severity and IL‐5 in chronic rhinosinusitis with nasal polyps
- Author
-
Kortekaas Krohn, I., primary, Bobic, S., additional, Dooley, J., additional, Lan, F., additional, Zhang, N., additional, Bachert, C., additional, Steelant, B., additional, Bullens, D. M., additional, Liston, A., additional, Ceuppens, J. L., additional, Seys, S. F., additional, and Hellings, P. W., additional
- Published
- 2017
- Full Text
- View/download PDF
16. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration: patent application GB1519841.9 - PCT/EP2016/078547 & WO2017/089392A1
- Author
-
Van Woensel, Matthias, Wauthoz, Nathalie, Rosiere, Rémi, Mathieu, Véronique, Kiss, Robert, Lefranc, Florence, Steelant, B, Van Gool, Stefaan W, Mathivet, Thomas, Gerhardt, Holger, Amighi, Karim, and De Vleeschouwer, Steven
- Subjects
Sciences pharmaceutiques ,Sciences bio-médicales et agricoles - Abstract
info:eu-repo/semantics/published
- Published
- 2015
17. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis
- Author
-
Hellings, P. W., Akdis, C. A., Bachert, C., Bousquet, J., Pugin, B., Adriaensen, G., Advani, R., Agache, I., Anjo, C., Anmolsingh, R., Annoni, E., Bieber, T., Bizaki, A., Braverman, I., Callebaut, I., Castillo Vizuete, J. A., Chalermwatanachai, T., Chmielewski, R., Cingi, C., Cools, L., Coppije, C., Cornet, M. E., De Boeck, I., De Corso, E., De Greve, G., Doulaptsi, M., Edmiston, R., Erskine, S., Gevaert, E., Gevaert, P., Golebski, K., Hopkins, C., Hox, V., Jaeggi, C., Joos, G., Khwaja, S., Kjeldsen, A., Klimek, L., Koennecke, M., Krohn, I. Kortekaas, Krysko, O., Kumar, B. N., Langdon, C., Lange, B., Lekakis, G., Levie, P., Lourijsen, E., Lund, V. J., Martens, K., Moesges, R., Mullol, J., Nyembue, T. D., Palkonen, S., Philpott, C., Pimentel, J., Poirrier, A., Pratas, A. C., Prokopakis, E., Pujols, L., Rombaux, P., Schmidt-Weber, C., Segboer, C., Spacova, I., Staikuniene, J., Steelant, B., Steinsvik, E. A., Teufelberger, A., Van Gerven, L., Van Gool, K., Verbrugge, R., Verhaeghe, B., Virkkula, P., Vlaminck, S., Vries-Uss, E., Wagenmann, M., Zuberbier, T., Seys, S. F., Fokkens, W. J., Hellings, P. W., Akdis, C. A., Bachert, C., Bousquet, J., Pugin, B., Adriaensen, G., Advani, R., Agache, I., Anjo, C., Anmolsingh, R., Annoni, E., Bieber, T., Bizaki, A., Braverman, I., Callebaut, I., Castillo Vizuete, J. A., Chalermwatanachai, T., Chmielewski, R., Cingi, C., Cools, L., Coppije, C., Cornet, M. E., De Boeck, I., De Corso, E., De Greve, G., Doulaptsi, M., Edmiston, R., Erskine, S., Gevaert, E., Gevaert, P., Golebski, K., Hopkins, C., Hox, V., Jaeggi, C., Joos, G., Khwaja, S., Kjeldsen, A., Klimek, L., Koennecke, M., Krohn, I. Kortekaas, Krysko, O., Kumar, B. N., Langdon, C., Lange, B., Lekakis, G., Levie, P., Lourijsen, E., Lund, V. J., Martens, K., Moesges, R., Mullol, J., Nyembue, T. D., Palkonen, S., Philpott, C., Pimentel, J., Poirrier, A., Pratas, A. C., Prokopakis, E., Pujols, L., Rombaux, P., Schmidt-Weber, C., Segboer, C., Spacova, I., Staikuniene, J., Steelant, B., Steinsvik, E. A., Teufelberger, A., Van Gerven, L., Van Gool, K., Verbrugge, R., Verhaeghe, B., Virkkula, P., Vlaminck, S., Vries-Uss, E., Wagenmann, M., Zuberbier, T., Seys, S. F., and Fokkens, W. J.
- Abstract
The first European Rhinology Research Forum organized by the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) was held in the Royal Academy of Medicine in Brussels on 17th and 18th November 2016, in collaboration with the European Rhinologic Society (ERS) and the Global Allergy and Asthma European Network (GA2LEN). One hundred and thirty participants (medical doctors from different specialties, researchers, as well as patients and industry representatives) from 27 countries took part in the multiple perspective discussions including brainstorming sessions on care pathways and research needs in rhinitis and rhinosinusitis.The debates started with an overview of the current state of the art, including weaknesses and strengths of the current practices, followed by the identification of essential research needs, thoroughly integrated in the context of Precision Medicine (PM), with personalized care, prediction of success of treatment, participation of the patient and prevention of disease as key principles for improving current clinical practices. This report provides a concise summary of the outcomes of the brainstorming sessions of the European Rhinology Research Forum 2016.
- Published
- 2017
18. Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease
- Author
-
Steelant, B., primary, Seys, S.F., additional, Boeckxstaens, G., additional, Akdis, C.A., additional, Ceuppens, J.L., additional, and Hellings, P.W., additional
- Published
- 2017
- Full Text
- View/download PDF
19. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis
- Author
-
Hellings, P.W., primary, Akdis, C.A., additional, Bachert, C., additional, Bousquet, J., additional, Pugin, B., additional, Adriaensen, G., additional, Advani, R., additional, Agache, I., additional, Anjo, C., additional, Anmolsingh, R., additional, Annoni, E., additional, Bieber, T., additional, Bizaki, A., additional, Braverman, I., additional, Callebaut, I., additional, Castillo Vizuete, J.A., additional, Chalermwatanachai, T., additional, Chmielewski, R., additional, Cingi, C., additional, Cools, L., additional, Coppije, C., additional, Cornet, M.E., additional, de Boeck, I., additional, de Corso, E., additional, De Greve, G., additional, Doulaptsi, M., additional, Edmiston, R., additional, Erskine, S., additional, Gevaert, E., additional, Gevaert, P., additional, Golebski, K., additional, Hopkins, C., additional, Hox, V., additional, Jaeggi, C., additional, Joos, G., additional, Khwaja, S., additional, Kjeldsen, A., additional, Klimek, L., additional, Koennecke, M., additional, Kortekaas Krohn, I., additional, Krysko, O., additional, Kumar, B.N., additional, Langdon, C., additional, Lange, B., additional, Lekakis, G., additional, Levie, P., additional, Lourijsen, E., additional, Lund, V.J., additional, Martens, K., additional, Mösgens, R., additional, Mullol, J., additional, Nyembue, T.D., additional, Palkonen, S., additional, Philpott, C., additional, Pimentel, J., additional, Poirrier, A., additional, Pratas, A.C., additional, Prokopakis, E., additional, Pujols, L., additional, Rombaux, P., additional, Schmidt-Weber, C., additional, Segboer, C., additional, Spacova, I, additional, Staikuniene, J., additional, Steelant, B., additional, Steinsvik, E.A., additional, Teufelberger, A., additional, van Gerven, L., additional, van Gool, K., additional, Verbrugge, R., additional, Verhaeghe, B., additional, Virkkula, P., additional, Vlaminck, S., additional, Vries-Uss, E., additional, Wagenmann, M., additional, Zuberbier, T., additional, Seys, S.F., additional, and Fokkens, W.J., additional
- Published
- 2017
- Full Text
- View/download PDF
20. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration
- Author
-
Respiratory Drug Delivery (2016: 17-21/04/2016: Phoenix (Arizona)), Van Woensel, Matthias, Wauthoz, Nathalie, Rosiere, Rémi, Mathieu, Véronique, Kiss, Robert, Lefranc, Florence, Steelant, B, Van Gool, Stefaan W, Mathivet, Thomas, Gerhardt, Holger, Amighi, Karim, Respiratory Drug Delivery (2016: 17-21/04/2016: Phoenix (Arizona)), Van Woensel, Matthias, Wauthoz, Nathalie, Rosiere, Rémi, Mathieu, Véronique, Kiss, Robert, Lefranc, Florence, Steelant, B, Van Gool, Stefaan W, Mathivet, Thomas, Gerhardt, Holger, and Amighi, Karim
- Abstract
info:eu-repo/semantics/nonPublished
- Published
- 2016
21. Development of siRNA-loaded Chitosan Nanoparticles targeting Galectin-1 for the Treatment of Glioblastoma Multiforme via Intranasal Administration
- Author
-
Van Woensel, Matthias, Wauthoz, Nathalie, Rosiere, Rémi, Mathieu, Véronique, Kiss, Robert, Lefranc, Florence, Steelant, B, Van Gool, Stefaan W, Mathivet, Thomas, Gerhardt, Holger, Amighi, Karim, De Vleeschouwer, Steven, Van Woensel, Matthias, Wauthoz, Nathalie, Rosiere, Rémi, Mathieu, Véronique, Kiss, Robert, Lefranc, Florence, Steelant, B, Van Gool, Stefaan W, Mathivet, Thomas, Gerhardt, Holger, Amighi, Karim, and De Vleeschouwer, Steven
- Abstract
info:eu-repo/semantics/published
- Published
- 2016
22. Managing nasal valve compromise patients with nasal dilators: objective vs. subjective parameters
- Author
-
Lekakis, G., primary, Dekimpe, E., additional, Steelant, B., additional, and Steelant, P.W., additional
- Published
- 2016
- Full Text
- View/download PDF
23. Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease
- Author
-
Steelant, B., primary, Seys, S.F., additional, Boeckxstaens, G., additional, Akdis, C.A., additional, Ceuppens, J.L., additional, and Hellings, P.W., additional
- Published
- 2016
- Full Text
- View/download PDF
24. Regulation of melanocortin 1 receptor in allergic rhinitisin vitroandin vivo
- Author
-
Kleiner, S., primary, Braunstahl, G-J., additional, Rüdrich, U., additional, Gehring, M., additional, Eiz-Vesper, B., additional, Luger, T. A., additional, Steelant, B., additional, Seys, S. F., additional, Kapp, A., additional, Böhm, M., additional, Hellings, P. W., additional, and Raap, U., additional
- Published
- 2016
- Full Text
- View/download PDF
25. Regulation of melanocortin 1 receptor in allergic rhinitis in vitro and in vivo.
- Author
-
Kleiner, S., Braunstahl, G‐J., Rüdrich, U., Gehring, M., Eiz‐Vesper, B., Luger, T. A., Steelant, B., Seys, S. F., Kapp, A., Böhm, M., Hellings, P. W., and Raap, U.
- Subjects
HAY fever treatment ,MELANOCORTIN receptors ,ALLERGIES ,INFLAMMATION ,BASOPHILS ,PROVOCATION (Behavior) - Abstract
Background α-melanocyte-stimulating hormone (α- MSH) was shown to inhibit allergic airway inflammation and exert suppressive effects on human basophils. Objective This study aims to extend our current knowledge on the melanocortin 1 receptor ( MC1R) expression in nasal tissue of patients with allergic rhinitis ( AR) and functional effects of α- MSH in human basophils especially from patients with allergic rhinitis. Methods MC1R expression before and after nasal allergen provocation was studied in nasal mucosal tissue of AR patients and in a mouse model of allergic airway inflammation using immunofluorescence. In vitro regulation of the MC1R and CD203c surface expression on whole-blood basophils of patients with AR and controls was assessed with flow cytometry. Functional effects of α- MSH on isolated basophils were analysed regarding apoptosis with flow cytometry and chemotaxis using a Boyden chamber assay. Results We detected an accumulation of MC1R-positive basophils in nasal mucosa tissue of patients with AR 24 h after nasal allergen provocation. Such accumulation was not present in mucosa sections from healthy controls. In mice with allergic airway inflammation, we found a clear accumulation of MC1R-positive basophils in the nasal tissue compared to control mice. MC1R expression was inducible in AR patients and controls by stimulation with anti-IgE. α- MSH inhibited anti-IgE and grass pollen induced upregulation of CD203c, but had no effect on chemotaxis or apoptosis of basophils in vitro. Conclusions and Clinical Relevance MC1R-positive basophils accumulate in the nasal mucosa of patients with AR after nasal allergen provocation. Since α- MSH suppresses proinflammatory effector functions in human basophils via the MC1R, it constitutes an interesting novel target for modulating the allergic inflammatory response. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. The nasal basal cell population shifts toward a diseased phenotype with impaired barrier formation capacity in allergic rhinitis.
- Author
-
Ruysseveldt E, Steelant B, Wils T, Cremer J, Bullens DMA, Hellings PW, and Martens K
- Subjects
- Humans, Male, Female, Adult, Single-Cell Analysis, Middle Aged, Animals, Pyroglyphidae immunology, Epithelial Cells immunology, Epithelial Cells metabolism, Cells, Cultured, Rhinitis, Allergic immunology, Rhinitis, Allergic pathology, Nasal Mucosa immunology, Nasal Mucosa pathology, Phenotype
- Abstract
Background: The integrity of the airway epithelium is guarded by the airway basal cells that serve as progenitor cells and restore wounds in case of injury. Basal cells are a heterogenous population, and specific changes in their behavior are associated with chronic barrier disruption-mechanisms that have not been studied in detail in allergic rhinitis (AR)., Objective: We aimed to study basal cell subtypes in AR and healthy controls., Methods: Single-cell RNA sequencing (scRNA-Seq) of the nasal epithelium was performed on nonallergic and house dust mite-allergic AR patients to reveal basal cell diversity and to identify allergy-related alterations. Flow cytometry, immunofluorescence staining, and in vitro experiments using primary basal cells were performed to confirm phenotypic findings at the protein level and functionally., Results: The scRNA-Seq, flow cytometry, and immunofluorescence staining revealed that basal cells are abundantly and heterogeneously present in the nasal epithelium, suggesting specialized subtypes. The total basal cell fraction within the epithelium in AR is increased compared to controls. scRNA-Seq demonstrated that potentially beneficial basal cells are missing in AR epithelium, while an activated population of allergy-associated basal cells is more dominantly present. Furthermore, our in vitro proliferation, wound healing assay and air-liquid interface cultures show that AR-associated basal cells have altered progenitor capacity compared to nonallergic basal cells., Conclusions: The nasal basal cell population is abundant and diverse, and it shifts toward a diseased state in AR. The absence of potentially protective subtypes and the rise of a proinflammatory population suggest that basal cells are important players in maintaining epithelial barrier defects in AR., Competing Interests: Disclosure statement The author’s laboratories are supported by grants from the research council of the KU Leuven (C14/18/086). T.W. is supported by a predoctoral grant of the Fund for Scientific Research Flanders (FWO), Belgium (11L8922N). B.S. received a postdoctoral fellowship from the Fund for Scientific Research Flanders (FWO), Belgium (12U6721N). K.M. received a junior postdoctoral fellowship from the Fund for Scientific Research Flanders (FWO), Belgium (12Z0622N). D.M.A.B. is a recipient of a senior clinical investigator grant of the Fund for Scientific Research Flanders (FWO), Belgium (1801014N) and from the Bijzonder Onderzoeksfonds—fundamenteel klinisch mandaat (BOF-FKM) of the KU Leuven (FKO CM23-FKO-02). Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Rare presence and function of neuroendocrine cells in the nasal mucosa.
- Author
-
Wils T, Backaert W, Jacobs I, Ruysseveldt E, Cremer J, Dilissen E, Bullens DM, Talavera K, Steelant B, Van Gerven L, Martens K, and Hellings PW
- Subjects
- Humans, Female, Adult, Male, Middle Aged, Sinusitis metabolism, Sinusitis pathology, Sinusitis immunology, Rhinitis, Allergic metabolism, Rhinitis, Allergic immunology, Rhinitis, Allergic pathology, Biomarkers, Basic Helix-Loop-Helix Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, Cells, Cultured, Nasal Mucosa metabolism, Nasal Mucosa pathology, Nasal Mucosa immunology, Neuroendocrine Cells metabolism, Neuroendocrine Cells pathology, Nasal Polyps immunology, Nasal Polyps pathology, Nasal Polyps metabolism
- Abstract
There is growing evidence that neurogenic inflammation contributes to the pathophysiology of upper airway diseases, with nasal hyperreactivity (NHR) being a key symptom. The rare neuroendocrine cells (NECs) in the epithelium have been linked to the pathophysiology of bronchial and intestinal hyperreactivity, however their presence in the nasal mucosa and their potential role in NHR remains unclear. Therefore, we studied the presence of NECs in the nasal epithelium of controls, allergic rhinitis patients and chronic rhinosinusitis with nasal polyps patients, and their link to NHR. The expression of typical NECs markers, CHGA, ASCL1 and CGRP, were evaluated on gene and protein level in human samples using real-time quantitative PCR (RT-qPCR), western blot, immunohistochemistry fluorescence staining, RNA scope assay, flow cytometry and single cell RNA-sequencing. Furthermore, the change in peak nasal inspiratory flow after cold dry air provocation and visual analogue scale scores were used to evaluate NHR or disease severity, respectively. Limited gene expression of the NECs markers CHGA and ASCL1 was measured in patients with upper airway diseases and controls. Gene expression of these markers did not correlate with NHR severity nor disease severity. In vitro , CHGA and ASCL1 expression was also evaluated in primary nasal epithelial cell cultures from patients with upper airway disease and controls using RT-qPCR and western blot. Both on gene and protein level only limited CHGA and ASCL1 expression was found. Additionally, NECs were studied in nasal biopsies of patients with upper airway diseases and controls using immunohistochemistry fluorescence staining, RNA scope and flow cytometry. Unlike in ileum samples, CHGA could not be detected in nasal biopsies of patients with upper airway diseases and control subjects. Lastly, single cell RNA-sequencing of upper airway tissue could not identify a NEC cluster. In summary, in contrast to the bronchi and gut, there is only limited evidence for the presence of NECs in the nasal mucosa, and without correlation with NHR, thereby questioning the relevance of NECs in upper airway pathology., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Wils, Backaert, Jacobs, Ruysseveldt, Cremer, Dilissen, Bullens, Talavera, Steelant, Van Gerven, Martens and Hellings.)
- Published
- 2024
- Full Text
- View/download PDF
28. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
- Author
-
Van Broeck D, Steelant B, Scadding G, and Hellings PW
- Abstract
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin/NSAID. It affects approximately 15% cases of severe asthma, 10% of nasal polyps and 9% of rhinosinusitis. N-ERD results in associated asthma exacerbations, oral corticosteroids bursts, corticosteroid-dependent disease, and multiple endoscopic sinus surgeries. Unknown influences cause polyp epithelium to release alarmins, such as IL-33 and TSLP. These cytokines activate lymphoid cells, both Th2 and ILC2, to release cytokines such as IL5, IL4 and IL13, resulting in complex type 2 inflammation involving mast cells, eosinophils and platelets. Arachidonic acid released from such cells is metabolized into mediators. N-ERD is characterized by an imbalance in eicosanoid levels, especially CysLTs, PDG and PGE2. Patients with N-ERD present nasal symptoms (congestion, hyposmia/anosmia, nasal discharge) and lower airways symptoms (cough, sneezing, shortness of breath, chest tightness), anosmia, severe hyposmia as well as severe asthma which impacts the quality of life in this disease and leads to safety concerns in patients daily lives. Despite the variety of treatment strategies, the likelihood of recurrence of symptoms is high in patients with N-ERD. The most important strategies for treating N-ERD are listed as following: drug therapies, aspirin desensitization, monoclonal antibodies and other therapies associated. N-ERD treatment remains a major challenge in the current situation. Selecting the appropriate patient for aspirin desensitization, monoclonal antibodies or both is essential. This review provides an overview on aspirin desensitization and biologics in N-ERD and might help in decision making from both the perspective of the physician and patient. Patient characteristics, safety, efficacy, health care costs, but also patient preferences are all factors to take into account when it comes to a choice between biologics or aspirin desensitization., Competing Interests: The authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2023 Van Broeck, Steelant, Scadding and Hellings.)
- Published
- 2023
- Full Text
- View/download PDF
29. Determination of the chronic upper airway inflammatory phenotype using a symptom-score-based algorithm.
- Author
-
Backaert W, Steelant B, Guler I, Talavera K, Jorissen M, Schrijvers R, Hellings PW, and Van Gerven L
- Subjects
- Humans, Phenotype, Algorithms
- Published
- 2023
- Full Text
- View/download PDF
30. Peribronchial Inflammation Resulting from Regulatory T Cell Deficiency Damages the Respiratory Epithelium and Disturbs Barrier Function.
- Author
-
Jonckheere AC, Steelant B, Seys SF, Cremer J, Dilissen E, Boon L, Liston A, Schrijvers R, Breynaert C, Vanoirbeek JAJ, Ceuppens JL, and Bullens DMA
- Subjects
- Abatacept pharmacology, Amphiregulin metabolism, Animals, Cytokines metabolism, Forkhead Transcription Factors metabolism, Heparin-binding EGF-like Growth Factor metabolism, Inflammation metabolism, Interleukin-10 metabolism, Interleukin-33 metabolism, Interleukin-5 metabolism, Interleukin-6 metabolism, Mice, Mice, Inbred C57BL, RNA, Messenger metabolism, Respiratory Mucosa metabolism, Diphtheria Toxin, T-Lymphocytes, Regulatory metabolism
- Abstract
Regulatory T cells (Tregs) that express the transcription factor Foxp3 have a critical role in limiting inflammatory processes and tissue damage. Whether Tregs are functional in maintaining epithelial barriers and in control of tight junction expression has not yet been explored. In this study, we investigated the effect of Treg deficiency on the airway epithelial barrier in an experimental murine model in which diphtheria toxin was repeatedly injected in Foxp3-diphtheria toxin receptor (DTR) mice to deplete Tregs. This resulted in spontaneous peribronchial inflammation and led to a systemic and local increase of IL-4, IL-5, CCL3, IFN-γ, and IL-10 and a local (lung) increase of IL-6 and IL-33 and decreased amphiregulin levels. Moreover, Treg depletion increased airway permeability and decreased epithelial tight junction (protein and mRNA) expression. CTLA4-Ig treatment of Treg-depleted mice almost completely prevented barrier dysfunction together with suppression of lung inflammation and cytokine secretion. Treatment with anti-IL-4 partly reversed the effects of Treg depletion on tight junction expression, whereas neutralization of IL-6 of IFN-γ had either no effect or only a limited effect. We conclude that Tregs are essential to protect the epithelial barrier at the level of tight junctions by restricting spontaneous T cell activation and uncontrolled secretion of cytokines, in particular IL-4, in the bronchi., (Copyright © 2022 by The American Association of Immunologists, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
31. Corrigendum: Innate lymphoid cells are required to induce airway hyperreactivity in a murine neutrophilic asthma model.
- Author
-
Jonckheere AC, Seys SF, Steelant B, Decaesteker T, Dekoster K, Cremer J, Dilissen E, Schols D, Iwakura Y, Vande Velde G, Breynaert C, Schrijvers R, Vanoirbeek J, Ceuppens JL, Dupont LJ, and Bullens DMA
- Abstract
[This corrects the article DOI: 10.3389/fimmu.2022.849155.]., (Copyright © 2022 Jonckheere, Seys, Steelant, Decaesteker, Dekoster, Cremer, Dilissen, Schols, Iwakura, Vande Velde, Breynaert, Schrijvers, Vanoirbeek, Ceuppens, Dupont and Bullens.)
- Published
- 2022
- Full Text
- View/download PDF
32. Innate Lymphoid Cells Are Required to Induce Airway Hyperreactivity in a Murine Neutrophilic Asthma Model.
- Author
-
Jonckheere AC, Seys SF, Steelant B, Decaesteker T, Dekoster K, Cremer J, Dilissen E, Schols D, Iwakura Y, Vande Velde G, Breynaert C, Schrijvers R, Vanoirbeek J, Ceuppens JL, Dupont LJ, and Bullens DMA
- Subjects
- Animals, Cytokines, Disease Models, Animal, Humans, Immunity, Innate, Inflammation, Lipopolysaccharides pharmacology, Lymphocytes, Mice, Mice, Inbred BALB C, Mice, SCID, Asthma, Interleukin-17 pharmacology
- Abstract
Rationale: Non-allergic asthma is driven by multiple endotypes of which neutrophilic and pauci-granulocytic asthma have been best established. However, it is still puzzling what drives inflammation and airway hyperreactivity (AHR) in these patients and how it can be treated effectively. Recently, a potential role of the innate immune system and especially the innate lymphoid cells (ILC) has been proposed., Objective: In this study, we investigated the effects of LPS inhalation on airway inflammation and AHR as a potential model for elucidating the pathogenesis of non-allergic asthma., Methods: Wild-type (BALB/c), SCID, IL-17A
-/- , and Rag2-/- γC-/- mice were endonasally exposed to lipopolysaccharide (LPS, 2 µg) on four consecutive days. Twenty-four hours after the last exposure, AHR to methacholine was assessed. Cytokine levels and ILC subpopulations were determined in lung tissue. Cellular differential analysis was performed in BAL fluid., Main Results: In this study, we developed a murine model for non-allergic neutrophilic asthma. We found that repeated endonasal applications of low-dose LPS in BALB/c mice led to AHR, BAL neutrophilia, and a significant increase in lung ILC3 as well as a significant increase in lung chemokines KC and MIP-2 and cytokines IL-1β, IL-17A, IL-22, and TNF. The adoptive transfer of ILC in Rag2-/- γC-/- mice showed that ILC played a causal role in the induction of AHR in this model. Antagonising IL-1β, but not IL-17A or neutrophils, resulted in a partial reduction in LPS-induced AHR., Conclusion: In conclusion, we report here a murine model for neutrophilic asthma where ILC are required to induce airway hyperreactivity., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Jonckheere, Seys, Steelant, Decaesteker, Dekoster, Cremer, Dilissen, Schols, Iwakura, Vande Velde, Breynaert, Schrijvers, Vanoirbeek, Ceuppens, Dupont and Bullens.)- Published
- 2022
- Full Text
- View/download PDF
33. Erratum: Lacticaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis With Nasal Polyps.
- Author
-
Martens K, De Boeck I, Jokicevic K, Kiekens F, Farré R, Vanderveken OM, Seys SF, Lebeer S, Hellings PW, and Steelant B
- Abstract
This corrects the article on p. 560 in vol. 13, PMID: 34212544., (Copyright © 2022 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease.)
- Published
- 2022
- Full Text
- View/download PDF
34. Self-reported nasal hyperreactivity is common in all chronic upper airway inflammatory phenotypes and not related to general well-being.
- Author
-
Backaert W, Steelant B, Jorissen M, Van Oudenhove L, Talavera K, Hellings PW, and Van Gerven L
- Subjects
- Chronic Disease, Humans, Phenotype, Self Report, Nasal Polyps, Rhinitis epidemiology
- Published
- 2021
- Full Text
- View/download PDF
35. Airway Basal Cells, Protectors of Epithelial Walls in Health and Respiratory Diseases.
- Author
-
Ruysseveldt E, Martens K, and Steelant B
- Abstract
The airway epithelium provides a critical barrier to the outside environment. When its integrity is impaired, epithelial cells and residing immune cells collaborate to exclude pathogens and to heal tissue damage. Healing is achieved through tissue-specific stem cells: the airway basal cells. Positioned near the basal membrane, airway basal cells sense and respond to changes in tissue health by initiating a pro-inflammatory response and tissue repair via complex crosstalks with nearby fibroblasts and specialized immune cells. In addition, basal cells have the capacity to learn from previous encounters with the environment. Inflammation can indeed imprint a certain memory on basal cells by epigenetic changes so that sensitized tissues may respond differently to future assaults and the epithelium becomes better equipped to respond faster and more robustly to barrier defects. This memory can, however, be lost in diseased states. In this review, we discuss airway basal cells in respiratory diseases, the communication network between airway basal cells and tissue-resident and/or recruited immune cells, and how basal cell adaptation to environmental triggers occurs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ruysseveldt, Martens and Steelant.)
- Published
- 2021
- Full Text
- View/download PDF
36. Taste Receptors: The Gatekeepers of the Airway Epithelium.
- Author
-
Martens K, Steelant B, and Bullens DMA
- Subjects
- Animals, Humans, Models, Biological, Receptors, G-Protein-Coupled genetics, Respiratory System pathology, Epithelium metabolism, Receptors, G-Protein-Coupled metabolism, Respiratory System metabolism, Taste
- Abstract
Taste receptors are well known for their role in the sensation of taste. Surprisingly, the expression and involvement of taste receptors in chemosensory processes outside the tongue have been recently identified in many organs including the airways. Currently, a clear understanding of the airway-specific function of these receptors and the endogenous activating/inhibitory ligands is lagging. The focus of this review is on recent physiological and clinical data describing the taste receptors in the airways and their activation by secreted bacterial compounds. Taste receptors in the airways are potentially involved in three different immune pathways (i.e., the production of nitric oxide and antimicrobial peptides secretion, modulation of ciliary beat frequency, and bronchial smooth muscle cell relaxation). Moreover, genetic polymorphisms in these receptors may alter the patients' susceptibility to certain types of respiratory infections as well as to differential outcomes in patients with chronic inflammatory airway diseases such as chronic rhinosinusitis and asthma. A better understanding of the function of taste receptors in the airways may lead to the development of a novel class of therapeutic molecules that can stimulate airway mucosal immune responses and could treat patients with chronic airway diseases.
- Published
- 2021
- Full Text
- View/download PDF
37. A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis.
- Author
-
Van Bulck P, Cools L, Soumya MS, Nyembue DT, Kabobo P, Zhang L, Scadding GK, Toskala E, Fokkens WJ, Steelant B, and Hellings PW
- Subjects
- Allergens, China, Democratic Republic of the Congo, Humans, India, Surveys and Questionnaires, Rhinitis, Allergic diagnosis, Rhinitis, Allergic epidemiology, Rhinitis, Allergic therapy
- Abstract
Background: Recent data show uncontrolled disease in 35% of allergic rhinitis (AR) patients on medical treatment. The reasons for uncontrolled disease can arbitrarily be divided into disease-related, diagnosis-related, treatment-related, and patient-related factors. However, the relative importance of these factors in uncontrolled disease remains speculative. This explorative study aimed at determining the factors causing uncontrolled AR on four different continents worldwide, identifying the most common reasons for uncontrolled disease in AR., Methods: Patients with uncontrolled AR (n = 430) were asked to fill out a questionnaire and underwent a clinical examination at the outpatient clinic in five university outpatient clinics (Leuven [Belgium], Beijing [China], Kinshasa [Congo], Bangalore [India], and Philadelphia [US]). Two independent physicians evaluated the reason or multiple reasons for uncontrolled disease. The study was coordinated from the University Hospital of Leuven., Results: In uncontrolled AR patients, 76% of patients showed two or more reasons for uncontrolled disease according to the physicians' evaluation. Disease-related factors (64%) were considered most often the reason for uncontrolled disease, followed by treatment- (56%), patient- (54%), and diagnosis-related (47%) factors. There is limited variability in observations across different centers worldwide., Conclusion: We here define the multiple reasons for uncontrolled AR across different continents, with disease-related factors being most frequently associated with uncontrolled disease. A better understanding of uncontrolled disease will guide us in defining strategies to improve AR care., (© 2021 ARS-AAOA, LLC.)
- Published
- 2021
- Full Text
- View/download PDF
38. Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis.
- Author
-
Doulaptsi M, Wils T, Hellings PW, Martens K, Farré R, Vicario M, Fokkens W, Prokopakis E, and Steelant B
- Abstract
Tight junction defects (TJ) have been associated with a defective epithelial barrier function in allergic rhinitis (AR). Intranasal corticosteroids are potent drugs frequently used to treat AR and are shown to restore epithelial integrity by acting on TJs and by reducing type 2 cytokine production. However, the effect of different classes of intranasal corticosteroids on the epithelial barrier has not been studied. Therefore, we compared the effect of 2 intranasal corticosteroids, ie, fluticasone furoate (FF) and mometasone furoate (MF) on epithelial barrier function. Both FF and MF similarly increased trans-epithelial electrical resistance of primary nasal epithelial cell cultures from AR patients. In a house dust mite-induced allergic asthma mouse model, FF and MF had similar beneficial effects on fluorescein isothiocyanate-dextran 4 kDa mucosal permeability, eosinophilic infiltration and IL-13 levels. Both molecules increased mRNA expression of the TJ proteins occludin and zonula occludens-1, thereby restoring epithelial barrier function. Lastly, we showed that long-term FF treatment also increased expression of occludin in AR patients compared to controls. In conclusion, both FF and MF effectively restore epithelial barrier function by increasing expression of TJ proteins in AR patients., Competing Interests: The authors declare no competing interest in relation to this research., (© 2021 Published by Elsevier Inc. on behalf of World Allergy Organization.)
- Published
- 2021
- Full Text
- View/download PDF
39. Tackling nasal symptoms in athletes: Moving towards personalized medicine.
- Author
-
Hox V, Beyaert S, Bullens D, Couto M, Langer D, Hellings PW, Huart C, Rombaux P, Seys SF, Surda P, Walker A, and Steelant B
- Subjects
- Athletes, Exercise, Humans, Quality of Life, Precision Medicine, Sports
- Abstract
Adequate nasal breathing is indispensable for athletes, and nasal symptoms have been shown to interfere with their subjective feeling of comfortable breathing and quality of life. Nasal symptoms are caused by either structural abnormalities or mucosal pathology. Structural pathologies are managed differently from mucosal disease, and therefore, adequate diagnosis is of utmost importance in athletes in order to choose the correct treatment option for the individual. Literature suggests that nasal symptoms are more prevalent in athletes compared to the general population and certain sports environments might even trigger the development of symptoms. Given the high demands of respiratory function in athletes, insight into triggering factors is of high importance for disease prevention. Also, it has been suggested that athletes are more neglectful to their symptoms and hence remain undertreated, meaning that special attention should be paid to education of athletes and their caregivers. This review aims at giving an overview of nasal physiology in exercise as well as the possible types of nasal pathology. Additionally, diagnostic and treatment options are discussed and we focus on unmet needs for the management and prevention of these symptoms in athletes within the concept of precision medicine., (© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
40. The nasal mutualist Dolosigranulum pigrum AMBR11 supports homeostasis via multiple mechanisms.
- Author
-
De Boeck I, Wittouck S, Martens K, Spacova I, Cauwenberghs E, Allonsius CN, Jörissen J, Wuyts S, Van Beeck W, Dillen J, Bron PA, Steelant B, Hellings PW, Vanderveken OM, and Lebeer S
- Abstract
Comparing the nasal microbiome of healthy individuals and chronic rhinosinusitis (CRS) patients revealed Dolosigranulum pigrum as a species clearly associated with nasal health, although isolates obtained from healthy individuals are scarce. In this study, we explored the properties of this understudied lactic acid bacterium by integrating comparative genomics, habitat mining, cultivation, and functional characterization of interaction capacities. Mining 10.000 samples from the Earth Microbiome Project of 17 habitat types revealed that Dolosigranulum is mainly associated with the human nasal cavity. D. pigrum AMBR11 isolated from the nose of a healthy individual exerted antimicrobial activity against Staphylococcus aureus , decreased proinflammatory cytokine production in airway epithelial cells, and Galleria mellonella larvae mortality induced by this important nasal pathobiont. Furthermore, the strain protected the nasal barrier function in a mouse model using interleukin-4 as disruptive cytokine. Hence, D. pigrum AMBR11 is a mutualist with high potential as topical live biotherapeutic product., Competing Interests: A patent application (PCT/EP2019/086763) has been filed on 20 December 2019 related to this work. P.B. is a consultant for multiple companies in the food and health industry, but they were not involved in this manuscript. The remaining authors have no conflicts of interest to declare., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
41. Lacticaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis With Nasal Polyps.
- Author
-
Martens K, De Boeck I, Jokicevic K, Kiekens F, Farré R, Vanderveken OM, Seys SF, Lebeer S, Hellings PW, and Steelant B
- Abstract
Purpose: A defective epithelial barrier has been demonstrated in chronic rhinosinusitis with nasal polyps (CRSwNP). Lactobacilli are shown to restore epithelial barrier defects in gastrointestinal disorders, but their effect on the airway epithelial barrier is unknown. In this study, hence, we evaluated whether the nasopharyngeal isolates Lacticaseibacillus casei AMBR2 and Latilactobacillus sakei AMBR8 could restore nasal epithelial barrier integrity in CRSwNP., Methods: Ex vivo trans-epithelial tissue resistance and fluorescein isothiocyanate-dextran 4 kDa (FD4) permeability of nasal mucosal explants were measured. The relative abundance of lactobacilli in the maxillary sinus of CRSwNP patients was analyzed by amplicon sequencing of the V4 region of the 16S rRNA gene. The effect of spray-dried L. casei AMBR2 and L. sakei AMBR8 on epithelial integrity was investigated in vitro in primary nasal epithelial cells (pNECs) from healthy controls and patients with CRSwNP as well as in vivo in a murine model of interleukin (IL)-4 induced barrier dysfunction. The activation of Toll-like receptor 2 (TLR2) was explored in vitro by using polyclonal antibodies., Results: Patients with CRSwNP had a defective epithelial barrier which positively correlated with the relative abundance of lactobacilli-specific amplicons in the maxillary sinus. L. casei AMBR2, but not L. sakei AMBR8, increased the trans-epithelial electrical resistance (TEER) of pNECs from CRSwNP patients in a time-dependent manner. Treatment of epithelial cells with L. casei AMBR2 promoted the tight junction proteins occludin and zonula occludens-1 reorganization. Furthermore, L. casei AMBR2 prevented IL-4-induced nasal permeability in vivo and in vitro . Finally, the beneficial effect of L. casei AMBR2 on nasal epithelial cells in vitro was TLR2-dependent as blocking TLR2 receptors prevented the increase in TEER., Conclusions: A defective epithelial barrier in CRSwNP may be associated with a decrease in relative abundance of lactobacilli-specific amplicons. L. casei AMBR2 would restore nasal epithelial integrity and can be a novel therapeutic strategy for CRSwNP., Competing Interests: There are no financial or other issues that might lead to conflict of interest., (Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.)
- Published
- 2021
- Full Text
- View/download PDF
42. Brain activation after nasal histamine provocation in house dust mite allergic rhinitis patients.
- Author
-
Callebaut I, Steelant B, Backaert W, Peeters R, Sunaert S, Van Oudenhove L, and Hellings PW
- Subjects
- Animals, Brain, Dust, Histamine, Humans, Nasal Provocation Tests, Pyroglyphidae, Mites, Rhinitis, Allergic diagnosis
- Published
- 2021
- Full Text
- View/download PDF
43. A TRiP Through the Roles of Transient Receptor Potential Cation Channels in Type 2 Upper Airway Inflammation.
- Author
-
Backaert W, Steelant B, Hellings PW, Talavera K, and Van Gerven L
- Subjects
- Cations, Humans, Inflammation, Rhinitis, Allergic, Sinusitis, Transient Receptor Potential Channels
- Abstract
Purpose of Review: Despite their high prevalence, the pathophysiology of allergic rhinitis (AR) and chronic rhinosinusitis (CRS) remains unclear. Recently, transient receptor potential (TRP) cation channels emerged as important players in type 2 upper airway inflammatory disorders. In this review, we aim to discuss known and yet to be explored roles of TRP channels in the pathophysiology of AR and CRS with nasal polyps., Recent Findings: TRP channels participate in a plethora of cellular functions and are expressed on T cells, mast cells, respiratory epithelial cells, and sensory neurons of the upper airways. In chronic upper airway inflammation, TRP vanilloid 1 is mostly studied in relation to nasal hyperreactivity. Several other TRP channels such as TRP vanilloid 4, TRP ankyrin 1, TRP melastatin channels, and TRP canonical channels also have important functions, rendering them potential targets for therapy. The role of TRP channels in type 2 inflammatory upper airway diseases is steadily being uncovered and increasingly recognized. Modulation of TRP channels may offer therapeutic perspectives.
- Published
- 2021
- Full Text
- View/download PDF
44. Staphylococcus aureus enterotoxin B disrupts nasal epithelial barrier integrity.
- Author
-
Martens K, Seys SF, Alpizar YA, Schrijvers R, Bullens DMA, Breynaert C, Lebeer S, and Steelant B
- Subjects
- Adolescent, Adult, Aged, Animals, Case-Control Studies, Cell Line, Female, Humans, In Vitro Techniques, Interleukin-6 metabolism, Interleukin-8 metabolism, Male, Mice, Mice, Knockout, Middle Aged, Nasal Mucosa metabolism, Occludin drug effects, Occludin genetics, Primary Cell Culture, RNA, Messenger drug effects, RNA, Messenger metabolism, Staphylococcus aureus pathogenicity, Tight Junctions genetics, Toll-Like Receptor 2 antagonists & inhibitors, Toll-Like Receptor 2 genetics, Young Adult, Zonula Occludens-1 Protein drug effects, Zonula Occludens-1 Protein genetics, Enterotoxins pharmacology, Nasal Mucosa drug effects, Nasal Polyps metabolism, Permeability drug effects, Rhinitis metabolism, Sinusitis metabolism, Tight Junctions drug effects
- Abstract
Background: Staphylococcus aureus colonization and release of enterotoxin B (SEB) has been associated with severe chronic rhinosinusitis with nasal polyps (CRSwNP). The pathogenic mechanism of SEB on epithelial barriers, however, is largely unexplored., Objective: We investigated the effect of SEB on nasal epithelial barrier function., Methods: SEB was apically administered to air-liquid interface (ALI) cultures of primary polyp and nasal epithelial cells of CRSwNP patients and healthy controls, respectively. Epithelial cell integrity and tight junction expression were evaluated. The involvement of Toll-like receptor 2 (TLR2) activation was studied in vitro with TLR2 monoclonal antibodies and in vivo in tlr2
-/- knockout mice., Results: SEB applied to ALI cultures of polyp epithelial cells decreased epithelial cell integrity by diminishing occludin and zonula occludens (ZO)-1 protein expression. Antagonizing TLR2 prevented SEB-induced barrier disruption. SEB applied in the nose of control mice increased mucosal permeability and decreased mRNA expression of occludin and ZO-1, whereas mucosal integrity and tight junction expression remained unaltered in tlr2-/- mice. Furthermore, in vitro SEB stimulation resulted in epithelial production of IL-6 and IL-8, which was prevented by TLR2 antagonization., Conclusion & Clinical Relevance: SEB damages nasal polyp epithelial cell integrity by triggering TLR2 in CRSwNP. Our results suggest that SEB might represent a driving factor of disease exacerbation, rather than a causal factor for epithelial defects in CRSwNP. Interfering with TLR2 triggering might provide a way to avoid the pathophysiological consequences of S. aureus on inflammation in CRSwNP., (© 2020 John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
45. Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: A randomized, double-blind, placebo-controlled trial.
- Author
-
Van Gerven L, Steelant B, Cools L, Callebaut I, Backaert W, de Hoon J, Ampe E, Talavera K, and Hellings PW
- Subjects
- Administration, Intranasal, Adolescent, Adult, Capsaicin adverse effects, Double-Blind Method, Female, Humans, Male, Middle Aged, Rhinitis immunology, Rhinitis pathology, Capsaicin administration & dosage, Nasal Sprays, Rhinitis drug therapy
- Published
- 2021
- Full Text
- View/download PDF
46. Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma.
- Author
-
Feijen J, Seys SF, Steelant B, Bullens DMA, Dupont LJ, García-Cruz M, Jimenez-Chobillón A, Larenas-Linnemann D, Van Gerven L, Fokkens WJ, Agache I, and Hellings PW
- Abstract
Background: Nasal hyperreactivity (NHR) is a common feature of various rhinitis subtypes and represents a novel phenotype of rhinitis. It is being reported in two-thirds of adult rhinitis patients irrespective of the atopic status. Data on the prevalence of NHR in patients with asthma are lacking, as well as the nature of evoking triggers., Methods: Postal questionnaires were distributed to an unselected group of asthmatic patients in Leuven (Belgium, n = 190) and completed by 114 patients. In Mexico City (Mexico) and Brasov (Romania), respectively, 97 out of 110 and 80 out of 100 asthmatic patients attending the outpatient clinic completed the questionnaire. Non-asthmatic volunteers were recruited amongst university and hospital co-workers in Leuven (n = 53). The presence of self-reported NHR, the type of triggers evoking nasal and bronchial symptoms, medication use, self-reported allergy, and environmental factors were evaluated., Results: Overall, 69% of asthma patients reported NHR, with 32% having more than 4 triggers evoking NHR. These triggers included mainly exposure to temperature and humidity changes, cigarette smoke, and strong odours. A higher prevalence of NHR was detected in allergic compared to non-allergic asthma patients (73% vs. 53% p < 0.01). The prevalence of NHR correlated with asthma severity, ranging from 63% (VAS ≤3) to 81% (VAS ≥7). BHR was found more frequently in patients with NHR compared to without NHR (89% vs. 53%, p < 0.0001)., Conclusion: NHR represents a clinical phenotype of upper airway disease affecting over two-thirds of asthma patients and correlates with asthma severity. Targeting NHR in patients with asthma is often overlooked and should be reinforced in the future to achieve better symptom control., Competing Interests: All authors state they have no conflict of interest in relation to this study and the results described in the manuscript., (© 2020 The Authors.)
- Published
- 2020
- Full Text
- View/download PDF
47. Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis.
- Author
-
Doulaptsi M, Steelant B, Prokopakis E, Ierodiakonou D, Tsinaslanidou Z, Cools L, Pugin B, Milioni A, Van Gerven L, Fokkens WJ, Constantinidis J, and Hellings PW
- Subjects
- Chronic Disease, Humans, Nasal Mucosa, Nose, Prevalence, Nasal Polyps, Rhinitis diagnosis, Rhinitis epidemiology, Sinusitis epidemiology
- Published
- 2020
- Full Text
- View/download PDF
48. Epithelial barriers in allergy and asthma.
- Author
-
Hellings PW and Steelant B
- Subjects
- Allergens immunology, Animals, Humans, Inflammation immunology, Respiratory System immunology, Asthma immunology, Epithelial Cells immunology, Hypersensitivity immunology, Respiratory Mucosa immunology
- Abstract
The respiratory epithelium provides a physical, functional, and immunologic barrier to protect the host from the potential harming effects of inhaled environmental particles and to guarantee maintenance of a healthy state of the host. When compromised, activation of immune/inflammatory responses against exogenous allergens, microbial substances, and pollutants might occur, rendering individuals prone to develop chronic inflammation as seen in allergic rhinitis, chronic rhinosinusitis, and asthma. The airway epithelium in asthma and upper airway diseases is dysfunctional due to disturbed tight junction formation. By putting the epithelial barrier to the forefront of the pathophysiology of airway inflammation, different approaches to diagnose and target epithelial barrier defects are currently being developed. Using single-cell transcriptomics, novel epithelial cell types are being unraveled that might play a role in chronicity of respiratory diseases. We here review and discuss the current understandings of epithelial barrier defects in type 2-driven chronic inflammation of the upper and lower airways, the estimated contribution of these novel identified epithelial cells to disease, and the current clinical challenges in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
49. Nasal epithelial barrier dysfunction increases sensitization and mast cell degranulation in the absence of allergic inflammation.
- Author
-
Kortekaas Krohn I, Seys SF, Lund G, Jonckheere AC, Dierckx de Casterlé I, Ceuppens JL, Steelant B, and Hellings PW
- Subjects
- Allergens, Animals, Cell Degranulation, Inflammation, Mice, Mice, Inbred BALB C, Ovalbumin, Mast Cells, Rhinitis, Allergic
- Abstract
Background: Increased epithelial permeability has been reported in allergic rhinitis, with histamine and type-2 inflammation being responsible for tight junction dysfunction. The impact of an epithelial barrier defect on allergic sensitization and mast cell (MC) degranulation remains speculative., Methods: Transepithelial passage of allergens was evaluated on primary human nasal epithelial cell cultures. Active sensitization was attempted by repeated intranasal ovalbumin (OVA) applications in Naïve mice. In a passive sensitization model, mice were injected with IgE to Dermatophagoides pteronyssinus (rDer p)2 and then exposed intranasally to the allergen. Chitosan was used to disrupt nasal epithelial integrity in vitro and in vivo., Results: Chitosan strongly reduced transepithelial electrical resistance and facilitated transepithelial allergen passage in cultured primary nasal epithelial cells. In vivo, intranasal chitosan affected occludin expression and facilitated allergen passage. After epithelial barrier disruption, intranasal OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage (BAL) compared to sham-OVA mice. Chitosan exposure, prior to rDer p2 allergen challenge in passively sensitized mice, resulted in increased β-hexosaminidase levels in serum and BAL compared to sham-rDer p2 mice. Intranasal treatment with the synthetic glucocorticoid fluticasone propionate prevented chitosan-induced barrier dysfunction, allergic sensitization, and MC degranulation., Conclusion: Epithelial barrier dysfunction facilitates transepithelial allergen passage, allergic sensitization, and allergen-induced MC degranulation even in the absence of inflammatory environment. These results emphasize the crucial role of an intact epithelial barrier in prevention of allergy., (© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
50. Diagnostic approach to occupational rhinitis: the role of nasal provocation tests.
- Author
-
Ronsmans S, Steelant B, Backaert W, Nemery B, and Van Gerven L
- Subjects
- Administration, Intranasal, Allergens administration & dosage, Allergens adverse effects, Allergens immunology, Allergy and Immunology standards, Humans, Irritants administration & dosage, Irritants adverse effects, Nasal Mucosa drug effects, Nasal Mucosa immunology, Nasal Provocation Tests standards, Occupational Diseases immunology, Practice Guidelines as Topic, Rhinitis, Allergic immunology, Mass Screening methods, Nasal Provocation Tests methods, Occupational Diseases diagnosis, Occupational Exposure adverse effects, Rhinitis, Allergic diagnosis
- Abstract
Purpose of Review: The diagnosis of occupational rhinitis is a challenge. Underdiagnosis is substantial as the clinical presentation is nonspecific and often no occupational history is taken. Detection of occupational rhinitis can be improved by including screening questions on occupational exposure in the assessment of every patient with adult-onset rhinitis., Recent Findings: Case reports, case series and epidemiological studies continuously demonstrate new sensitizers and irritants capable of inducing allergic or nonallergic (irritant-induced) occupational rhinitis. Recent reviews have focused on the value of immunological tests with specific IgE, skin prick tests or basophil activation tests in demonstrating sensitization to occupational agents. Nasal provocation tests (NPT) can establish a definite diagnosis of allergic occupational rhinitis. Several NPT guidelines have been published, however, focusing exclusively on standardized high-molecular weight allergens. When performing NPT with nonstandardized agents -- like most occupational sensitizers -- adapted protocols are needed., Summary: We provide pragmatic guidance to clinicians taking care of rhinitis patients on how to diagnose occupational rhinitis, based on recent insights from the literature. We focus on the challenges in the diagnostic work-up, on how to identify suspected causes, and on the role of NPT.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.